Table 2 Intra- and postoperative data and pathological findings between groups
UTUC | Total (N = 66) | Group 1 RANU N 50 (77%) | Group 2 Combined RANU and RARC N = 11 (16%) | Group 3 Robot-assisted segmental Ureterectomy N = 5 (7,6%) | p-Value |
|---|---|---|---|---|---|
Console time (minute), mean (SD) | 63 (34) | 69 (37) | 42 (15) | 73 (12) | 0.065 |
Pathological tumor stage, n (%)* | |||||
 pT0 | 5 (7,5) | 5 (10) | 0 | 0 | 0.18 |
 pTa | 11 (16) | 9 (18) | 0 | 2 (40) |  |
 pT1 | 12 (18) | 11 (22) | 0 | 1 (20) |  |
 pT2 | 13 (19,6) | 10 (20) | 2 (18) | 1 (20) |  |
 pT3 | 21 (32) | 15 (30) | 5 (45) | 1 (20) |  |
 pT4 | 4 (6) | 0 | 4 (36) | 0 |  |
Urothelial carcinoma grade*, n (%) | |||||
 0 | 5 (7,5) | 5 (10) | 0 | 0 | 0.3 |
 1 | 14 (21) | 11 (22) | 0 | 3 (60) |  |
 2 | 5 (7,5) | 5 (10) | 0 | 0 |  |
 3 | 42 (63) | 29 (58) | 11 (100) | 2 (40) |  |
Postoperative Chemotherapy | |||||
(yes. vs. none), n (%) | Â | Â | Â | Â | 0.3 |
2 cycles cisplatin-Gemcitabine, n (%) | 2 (3) | 0 | 2 (18) | 0 | Â |
3 cycles cisplatin-Gemcitabine, n (%) | 1 (1,5) | 1 (2) | 0 | 0 | Â |
4 cycles cisplatin-Gemcitabine, n (%) | 1 (1,5) | 0 | 1 (9) | 0 | Â |
6 cycles cisplatin-Gemcitabine, n (%) | 1 (1,5) | 0 | 1 (9) | 0 | Â |
Initiation of CI therapy, n (%) | 3 (4,5) | 1 (2) | 1 (9) | 1 (20) | Â |
Positive surgical margins (total), (%) | 1 (1,5) | 0 | 1 (9) | 0 | 0.8 |
Number of patients, who received a lymphadenectomy, n (%) | 20 (30) | 10 (20) | 9 (81) | 1 (20) | 0.001 |
Number of lymph nodes removed in patients, who received a lymphadenectomy, mean (SD) | 13.7 (13.7) | 7 (10) | 22 (13) | 2 (0) | 0.035 |
Number of patients, who had a lymphadenectomy and had metastases among the total number of surgically treated patients | 6/20 (33%) | 1/10 (10%) | 5/9 (55%) | 0/1 | 0.002 |
Length of hospitalization (days), mean (SD) | 8.1 (6.5) | 7.9 (7) | 10 (5.5) | 5.8 (1) | 0.4 |
Transfusion rate, n (%) | 6 (9%) | 4 (8) | 2 (18) | 0 | 0.6 |